Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure).

You may be able to join if

• 1. Participants who enter the study on stable NA are willing and able to cease their NA treatment in accordance with the NA cessation schedule
• 2. Capable of giving informed consent
• 209668 (B-Clear), 209348 (B-Together) and 212602 (B-Fine) participants: 3. Participants who have previously received at least 1 dose of bepirovirsen AND a. Achieved a complete response in the parent study and who maintained a response for 24 weeks until the EoS visit in their parent study, in the absence of rescue medication (defined as complete responders to bepirovirsen from the parent study) OR b. Demonstrated HBsAg reduction from parent study Baseline with HBsAg levels and HBV DNA for 24 weeks after the actual end of treatment regimen, in the absence of rescue medication and maintained until their EoS visit in the parent study.
• 202009 and 219288 (B-Well 1 & 2) participants: 4. Participants who have previously received at least 1 dose of bepirovirsen (or matching placebo where approrpiate) AND a. NA cessated at Week 48 in parent study and achieved HBsAg and HBV DNA, in the absence of rescue medication at the EOS visit (Week 96) in the parent study OR b. Achieved NA cessation criteria at Week 48 in parent study but have not stopped NA treatment, and are maintaining HBsAg and HBV DNA at EOS visit (Week 72) of parent study OR c. Did not achieve NA cessation criteria in parent study, but achieved HBsAg and HBV DNA at EOS visit (Week 72) of parent study
• 217023 (TH HBV ASO-001) participants: 5. Participants who have previously received at least 1 dose of bepirovirsen AND achieved HBsAg and HBV DNA at the EOS study visit in parent study